

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	otion					
Identifying Information	ation					
1. Given Name (First Name) Daniel C.	2. Surnai Baumga	me (Last Nar irt	me)	3. Date 18-October-2017		
4. Are you the corresponding author?	Yes	<b>✓</b> No	Correspond N/A	Corresponding Author's Name N/A		
5. Manuscript Title 2017-2018 ECCO Annual Disclosure of Po	otential C	onflicts of I	Interest			
6. Manuscript Identifying Number (if you kno	ow it)					
Section 2. The Work Under Co	nsidera	tion for P	ublication			
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interest of the submitted work (including statistical analysis, etc.)?  Relevant financial and Place a check in the appropriate boxes in of compensation) with entities as described.	st?	nited to gran	nts, data monitoring  No  the submitted  e whether you ha	work.	udy design, manuscript preparation,	ount
clicking the "Add +" box. You should rep	ort relatio	onships tha	t were <b>present d</b>			,
Are there any relevant conflicts of interest If yes, please fill out the appropriate info			No			
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Shire	<b>✓</b>	<b>✓</b>			Unrestricted research grant to conduct basic science research on 5-ASA effects on barrier function and carcinogenesis	
AbbVie	<b>✓</b>	<b>✓</b>			Speaker Fee, Scientific Advisory Boards. Travel Support, Support for Regional Gastroenterology Meeting	
Merck (MSD)	<b>✓</b>	<b>√</b>			Speaker Fee, Scientific Advisory Board, Travel Support, Support for Regional Gastroenterology Meeting	



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Takeda	<b>✓</b>	<b>✓</b>			Speaker Fee, Scientific Advisory Board, Travel Support, Support for Regional Gastroenterology Meeting
Biogen	<b>✓</b>	<b>✓</b>			Scientific Advisory Board
Foreward Pharma		<b>✓</b>			Scientific Advisory Board
Dr. Falk	<b>✓</b>	<b>✓</b>			Speaker Fee, Travel Support
Ferring	<b>✓</b>	$\checkmark$			Speaker Fee, Travel Support
Recordati	<b>✓</b>	<b>✓</b>			Speaker Fee, Support for Regional Gastroenterology Meeting
Nestlé	<b>✓</b>				Support for Regional Gastroenterology Meeting
Genentech (Roche Group)	<b>√</b>	<b>✓</b>			Scientific Advisory Board, Support for Regional Gastroenterology Meeting
Janssen	<b>✓</b>	<b>✓</b>			Scientific Advisory Board, Support for Regional Gastroenterology Meeting
Hitachi	<b>✓</b>				Support for Regional Gastroenterology Meeting, Unrestricted Research Grant
TiGenix		<b>✓</b>			Scientific Advisory Board
Shield Therapeutics	<b>✓</b>				Scientific Advisory Board, Support for Regional Gastroenterology Meeting
Pfizer	<b>✓</b>	<b>✓</b>			Scientific Advisory Board, Support for Regional Gastroenterology Meeting
BMS	<b>✓</b>	<b>✓</b>			Scientific Advisory Board, Support for Regional Gastroenterology Meeting
Celgene	✓				Scientific Advisory Board
Boehringer Ingelheim		<b>✓</b>			Scientific Advisory Board
Amgen		<b>✓</b>			Scientific Advisory Board
Section 4. Intellectual Propert	<u>*</u>				
Do you have any patents, whether plann	ed, pendi	ing or issue	d, broadly releva	nt to the	work? Yes Vo



Section 5.	Relationships not covered above				
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?				
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):				
No other relationships/conditions/circumstances that present a potential conflict of interest					
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement. On occasion, journals may ask authors to disclose further information about reported relationships.					
Section 6.	Disclosure Statement				
Based on the abo	ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box				

Dr. Baumgart reports grants and personal fees from Shire, grants and personal fees from AbbVie, grants and personal fees from Merck (MSD), grants and personal fees from Takeda, grants and personal fees from Biogen, personal fees from Foreward Pharma, grants and personal fees from Dr. Falk, grants and personal fees from Ferring, grants and personal fees from Recordati, grants from Nestlé, grants and personal fees from Genentech (Roche Group), grants and personal fees from Janssen, grants from Hitachi, personal fees from TiGenix, grants from Shield Therapeutics, grants and personal fees from Pfizer, grants and personal fees from BMS, grants from Celgene, personal fees from Boehringer Ingelheim, personal fees from Amgen, outside the submitted work;

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.